Several works suggest that TGF-β inhibition promotes leukemic transformation [24,25], and, specifically in CLL, this has been postulated [26,27,28,29], but the molecular mechanisms that regulate this pathway during CLL progression remain unknown. The gene discussed is TGFB1; the disease is B-cell chronic lymphocytic leukemia.